HRS-7249
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
September 16, 2025
HRS-7249-101: A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=48 | Completed | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting ➔ Completed
Trial completion • Dyslipidemia • APOB
September 11, 2025
A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia
(clinicaltrials.gov)
- P2 | N=200 | Recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Dyslipidemia
August 05, 2025
A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia
(clinicaltrials.gov)
- P2 | N=200 | Not yet recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
New P2 trial • Dyslipidemia
August 28, 2024
HRS-7249-101: A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Dyslipidemia
August 07, 2024
A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=48 | Not yet recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
New P1 trial • Dyslipidemia
1 to 5
Of
5
Go to page
1